Issue 59, 2018

In situ fluorescence monitoring of diagnosis and treatment: a versatile nanoprobe combining tumor targeting based on MUC1 and controllable DOX release by telomerase

Abstract

We have constructed versatile drug-loaded nanoprobes capable of responding to both MUC1 and telomerase and achieving intracellular drug release. Besides, the synthesized drug-loaded nanoprobes can realize the in situ imaging observation of the whole process of nanoprobes targeting the tumor cell membrane, the transmembrane entering the cytoplasm and the release of DOX into the cell nucleus.

Graphical abstract: In situ fluorescence monitoring of diagnosis and treatment: a versatile nanoprobe combining tumor targeting based on MUC1 and controllable DOX release by telomerase

Supplementary files

Article information

Article type
Communication
Submitted
25 Jun 2018
Accepted
02 Jul 2018
First published
02 Jul 2018

Chem. Commun., 2018,54, 8277-8280

In situ fluorescence monitoring of diagnosis and treatment: a versatile nanoprobe combining tumor targeting based on MUC1 and controllable DOX release by telomerase

H. Si, L. Wang, Q. Li, X. Li, L. Li and B. Tang, Chem. Commun., 2018, 54, 8277 DOI: 10.1039/C8CC05052J

To request permission to reproduce material from this article, please go to the Copyright Clearance Center request page.

If you are an author contributing to an RSC publication, you do not need to request permission provided correct acknowledgement is given.

If you are the author of this article, you do not need to request permission to reproduce figures and diagrams provided correct acknowledgement is given. If you want to reproduce the whole article in a third-party publication (excluding your thesis/dissertation for which permission is not required) please go to the Copyright Clearance Center request page.

Read more about how to correctly acknowledge RSC content.

Social activity

Spotlight

Advertisements